

Enrico Mini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8068802/enrico-mini-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

5,975
citations

37
h-index

75
g-index

148
ext. papers

6,815
ext. citations

5.6
avg. IF

5.24
L-index

#	Paper	IF	Citations
137	Gastric and colonic metastasis from NSCLC: A very unusual case report.. <i>Medicine (United States)</i> , 2022 , 101, e28249	1.8	0
136	Predictive Biomarkers of drug response: Colorectal cancer as a model 2022 , 199-240		0
135	Surgery for ulcerative colitis complicated with colorectal cancer: when ileal pouch-anal anastomosis is the right choice.. <i>Updates in Surgery</i> , 2022 , 74, 637	2.9	0
134	and Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. <i>Oncology Research</i> , 2021 , 28, 631-644	4.8	4
133	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. <i>Gastric Cancer</i> , 2021 , 24, 765-779	7.6	4
132	Maintenance in gastric cancer: New life for an old issue?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103307	7	1
131	Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 632256	5.3	4
130	Cyclodextrin Inclusion Complexes of Auranofin and Its Iodido Analog: A Chemical and Biological Study. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
129	Characterization and Separation of Platinum-Based Antineoplastic Drugs by Zwitterionic Hydrophilic Interaction Liquid Chromatography (HILIC) Tandem Mass Spectrometry, and Its Application in Surface Wipe Sampling. <i>Separations</i> , 2021 , 8, 69	3.1	2
128	Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. <i>Endocrine</i> , 2021 , 74, 172-179	4	2
127	Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e23520-e23520	2.2	
126	Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge. <i>Pharmacology & Therapeutics</i> , 2021 , 229, 107924	13.9	0
125	Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1353-1365	3.8	0
124	ALTERTASTE: improving food pleasure and intake of oncology patients receiving chemotherapy. <i>Future Oncology</i> , 2021 , 17, 2573-2579	3.6	1
123	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021 , 144, 101-112	7.5	4
122	Increased Expression of is Predictive of Lymph Node Metastasis in Colorectal Cancer: Results from a 20-Gene Expression Signature. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
121	The gut microbiome and efficacy of cancer immunotherapy. <i>Pharmacology & Therapeutics</i> , 2021 , 231, 107973	13.9	7

120	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 121-125	2.7	5
119	TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluoropyrimidine drug combination. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102987	7	3
118	TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 103011	7	8
117	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>Translational Oncology</i> , 2020 , 13, 100795	4.9	14
116	An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 149, 102921	7	3
115	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
114	Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
113	Perioperative chemotherapy for gastric cancer in FLOT4. <i>Lancet, The</i> , 2020 , 395, e3	40	3
112	Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. <i>Current Cancer Drug Targets</i> , 2020 , 20, 887-895	2.8	4
111	Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17093-e17093	2.2	
110	Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e23518-e23518	2.2	
109	Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. <i>Journal of Oncology</i> , 2020 , 2020, 8024124	4.5	1
108	Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. <i>Scientific Reports</i> , 2020 , 10, 19281	4.9	4
107	Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience. <i>Oncology Research</i> , 2020 , 28, 237-248	4.8	0
106	Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
105	Role of ATP-binding cassette transporters in cancer initiation and progression. <i>Seminars in Cancer Biology</i> , 2020 , 60, 72-95	12.7	24
104	Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties. <i>Journal of Inorganic Biochemistry</i> , 2020 , 208, 111079	4.2	17
103	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019 , 25, 3839-3846	12.9	90

102	RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. <i>International Journal of Cancer</i> , 2019 , 145, 2580-2593	7.5	16
101	Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2019 , 10, 656-660	4.3	40
100	Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919861905	5.4	21
99	Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. <i>Journal of Oncology</i> , 2019 , 2019, 5692317	4.5	5
98	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 1153-1161	4	7
97	Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16077-e16077	2.2	0
96	Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11032-11032	2.2	
95	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. <i>Frontiers in Oncology</i> , 2019 , 9, 1102	5.3	11
94	The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 994-1002	6.1	17
93	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 379-383	13.4	64
92	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2018 , 24, 4745-4753	12.9	14
91	Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study. <i>Oncotarget</i> , 2018 , 9, 28042-28068	3.3	40
90	Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3568-3568	2.2	
89	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. <i>JAMA Oncology</i> , 2018 , 4, e173695	13.4	37
88	Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	31
87	Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors. <i>Molecular and Clinical Oncology</i> , 2018 , 9, 635-639	1.6	1
86	Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. <i>Tumor Biology</i> , 2018 , 40, 1010428318815047	2.9	4
85	A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. <i>BMC Cancer</i> , 2018 , 18, 1024	4.8	2

84	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1101	5.6	4
83	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1146-1155	8.9	57
82	MA14.06 Nivolumab in Never Smoker Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP). <i>Journal of Thoracic Oncology</i> , 2017 , 12, S424-S425	8.9	2
81	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	138
80	The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. <i>Oncology Research</i> , 2017 , 25, 1441-1451	4.8	2
79	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017 , 82, 16-24	7.5	28
78	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3515-3515	2.2	3
77	Selection and characterization of a human ovarian cancer cell line resistant to auranofin. <i>Oncotarget</i> , 2017 , 8, 96062-96078	3.3	29
76	Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. <i>JAMA Oncology</i> , 2016 , 2, 643-653	13.4	87
75	Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. <i>Dalton Transactions</i> , 2016 , 45, 579-90	4.3	33
74	Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy. <i>Free Radical Biology and Medicine</i> , 2016 , 93, 67-76	7.8	26
73	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX +/- cetuximab: A PETACC8 translational study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 553-553	2.2	3
72	Enhanced Efficacy of Artemisinin Loaded in Transferrin-Conjugated Liposomes versus Stealth Liposomes against HCT-8 Colon Cancer Cells. <i>ChemMedChem</i> , 2016 , 11, 1745-51	3.7	32
71	Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication. <i>Molecular BioSystems</i> , 2015 , 11, 1653-67		9
70	Emerging drugs in refractory colorectal cancer. <i>Future Medicinal Chemistry</i> , 2015 , 7, 1491-501	4.1	2
69	In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2015 , 151, 285-96	6.7	12
68	Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. <i>International Journal of Cancer</i> , 2015 , 137, 2971-80	7.5	48
67	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3506-3506	2.2	2

66	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3507-3507	2.2	6
65	HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. <i>PLoS ONE</i> , 2015 , 10, e0144000	3.7	22
64	The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents. <i>Oncotarget</i> , 2015 , 6, 31985-96	3.3	7
63	Role of Genetic Polymorphisms on Response to R-Chopregimen in Diffuse Large B-Cell Lymphoma Patients: An Interim Analysis of a Multicenter Prospective Pharmacogenetic Study. <i>Blood</i> , 2015 , 126, 2483-2483	2.2	
62	Strategy to provide a useful solution to effective delivery of dihydroartemisinin: development, characterization and in vitro studies of liposomal formulations. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014 , 116, 121-7	6	37
61	Size dependent biological profiles of PEGylated gold nanorods. <i>Journal of Materials Chemistry B</i> , 2014 , 2, 6072-6080	7.3	34
60	Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters. <i>European Journal of Medicinal Chemistry</i> , 2014 , 87, 398-412	6.8	17
59	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 862-73	21.7	190
58	Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c). <i>Journal of Proteomics</i> , 2014 , 103, 103-20	3.9	30
57	Chemistry and biology of two novel gold(I) carbene complexes as prospective anticancer agents. <i>Inorganic Chemistry</i> , 2014 , 53, 2396-403	5.1	63
56	Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2071-8	1.9	5
55	New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR). <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 456-65	3.4	12
54	The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics. <i>Journal of Inorganic Biochemistry</i> , 2013 , 118, 94-9	4.2	35
53	Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: solution behavior, reactions with model proteins, antiproliferative properties. <i>Journal of Inorganic Biochemistry</i> , 2012 , 108, 123-7	4.2	32
52	Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. <i>Medicinal Research Reviews</i> , 2012 , 32, 1220-62	14.4	124
51	Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds. <i>Metallomics</i> , 2012 , 4, 307-14	4.5	33
50	2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. <i>Molecular BioSystems</i> , 2012 , 8, 985-93		22
49	Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2'-pyridyl)benzimidazole as ligand: comparisons of gold(III) versus gold(I) and mononuclear versus binuclear derivatives. <i>Inorganic Chemistry</i> , 2012 , 51, 3161-71	5.1	67

48	O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial. <i>Annals of Oncology</i> , 2012 , 23, iv17	10.3	5
47	Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. <i>Pharmacological Research</i> , 2011 , 64, 242-8	10.2	19
46	Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. <i>Drug Resistance Updates</i> , 2011 , 14, 280-96	23.2	89
45	Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. <i>International Journal of Cancer</i> , 2011 , 128, 1935-45	7.5	16
44	Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. <i>Journal of Inorganic Biochemistry</i> , 2011 , 105, 348-55	4.2	40
43	Genomic and genetic alterations influence the progression of gastric cancer. <i>World Journal of Gastroenterology</i> , 2011 , 17, 290-9	5.6	93
42	Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2011 , 118, 2478-2478	2.2	
41	Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 866-71	2.2	128
40	Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 1755-62	8.3	22
39	Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 1197-202	3.5	10
38	Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. <i>Journal of Biological Inorganic Chemistry</i> , 2010 , 15, 573-82	3.7	52
37	Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. <i>Medicinal Research Reviews</i> , 2010 , 30, 550-80	14.4	354
36	Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3117-25	2.2	354
35	N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 807-17	8.3	29
34	Natural compounds for cancer treatment and prevention. <i>Pharmacological Research</i> , 2009 , 59, 365-78	10.2	464
33	Pharmacogenetics: implementing personalized medicine. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2009 , 6, 17-24		28
32	High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. <i>American Journal of Clinical Pathology</i> , 2008 , 130, 247-53	1.9	146
31	Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 564-75	4.2	226

30	Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 9409-19	3.4	28
29	Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 5524-31	8.3	167
28	Mechanisms of cytotoxicity of selected organogold(III) compounds. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 6761-5	8.3	116
27	Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents. <i>Anti-Cancer Drugs</i> , 2005 , 16, 645-51	2.4	15
26	In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005 , 15, 3930-3	2.9	109
25	Solution chemistry and cytotoxic properties of novel organogold(III) compounds. <i>Bioorganic and Medicinal Chemistry</i> , 2004 , 12, 6039-43	3.4	68
24	Effect of methylenetetrahydrofolate reductase 677C->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. <i>International Journal of Cancer</i> , 2003 , 103, 294-9	7.5	107
23	Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 627-37	6.1	21
22	Clinical pharmacokinetics of depot leuprorelin. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 485-504	6.2	119
21	Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 1672-7	8.3	236
20	Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides. <i>Anti-Cancer Drugs</i> , 2000 , 11, 285-94	2.4	4
19	Resistance to methotrexate in SKOV-3 cell lines after chronic exposure to carbamazepine is associated with a decreased expression of folate receptor. <i>International Journal of Cancer</i> , 2000 , 85, 683-90	7.5	8
18	Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor. <i>International Journal of Cancer</i> , 2000 , 88, 525-34	7.5	16
17	Cytotoxicity and DNA binding properties of a chloro glycyhistidinate gold(III) complex (GHAu). <i>Chemico-Biological Interactions</i> , 2000 , 125, 29-38	5	44
16	Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. <i>Cancer Letters</i> , 2000 , 150, 71-8	9.9	19
15	Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 3541-8	8.3	282
14	Gold(III) compounds as potential antitumor agents: Cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes. <i>Inorganica Chimica Acta</i> , 1998 , 281, 90-94	2.7	58
13	Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues. <i>Gynecologic Oncology</i> , 1998 , 71, 396-403	4.9	11

12	Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat. <i>Cancer Letters</i> , 1998 , 125, 51-9	9.9	45
11	Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay. <i>Anti-Cancer Drugs</i> , 1997 , 8, 767-77	2.4	4
10	Biological properties of two gold(III) complexes: AuCl ₃ (Hpm) and AuCl ₂ (pm). <i>Journal of Inorganic Biochemistry</i> , 1997 , 66, 103-9	4.2	51
9	Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. <i>Anti-Cancer Drugs</i> , 1995 , 6, 398-404	2.4	31
8	Adverse effects of macrolide antibacterials. <i>Drug Safety</i> , 1993 , 9, 346-64	5.1	115
7	Pharmacokinetic drug interactions of macrolides. <i>Clinical Pharmacokinetics</i> , 1992 , 23, 106-31	6.2	249
6	Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma. <i>Cancer Investigation</i> , 1991 , 9, 249-55	2.1	12
5	Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). <i>Clinical Pharmacokinetics</i> , 1989 , 16, 193-214	6.2	73
4	Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II). <i>Clinical Pharmacokinetics</i> , 1989 , 16, 261-82	6.2	29
3	Effects of 5-methyltetrahydrofolate on the activity of fluoropyrimidines against human leukemia (CCRF-CEM) cells. <i>Biochemical Pharmacology</i> , 1987 , 36, 2905-11	6	26
2	Cytotoxic effects of hyperthermia, 5-fluorouracil and their combination on a human leukemia T-lymphoblast cell line, CCRF-CEM. <i>European Journal of Cancer & Clinical Oncology</i> , 1986 , 22, 927-34		13
1	Synthesis and evaluation of 2,4-diaminoquinazoline antifolates with activity against methotrexate-resistant human tumor cells. <i>Biochemical Pharmacology</i> , 1984 , 33, 3251-5	6	8